Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice

Ana María Martín-Moreno1,2, Begoña Brera1,2, Carlos Spuch2,3,8, Eva Carro2,3, Luis García-García4, Mercedes Delgado4, Miguel A Pozo4,5, Nadia G Innamorato2,6, Antonio Cuadrado2,6 and María L de Ceballos1,2*

Abstract

Background: Alzheimer’s disease (AD) brain shows an ongoing inflammatory condition and non-steroidal anti-inflammatories diminish the risk of suffering the neurologic disease. Cannabinoids are neuroprotective and anti-inflammatory agents with therapeutic potential.

Methods: We have studied the effects of prolonged oral administration of transgenic amyloid precursor protein (APP) mice with two pharmacologically different cannabinoids (WIN 55,212-2 and JWH-133, 0.2 mg/kg/day in the drinking water during 4 months) on inflammatory and cognitive parameters, and on 18F-fluoro-deoxyglucose (18FDG) uptake by positron emission tomography (PET).

Results: Novel object recognition was significantly reduced in 11 month old Tg APP mice and 4 month administration of JWH was able to normalize this cognitive deficit, although WIN was ineffective. Wild type mice cognitive performance was unaltered by cannabinoid administration. Tg APP mice showed decreased 18FDG uptake in hippocampus and cortical regions, which was counteracted by oral JWH treatment. Hippocampal GFAP immunoreactivity and cortical protein expression was unaffected by genotype or treatment. In contrast, the density of Iba1 positive microglia was increased in Tg APP mice, and normalized following JWH chronic treatment. Both cannabinoids were effective at reducing the enhancement of COX-2 protein levels and TNF-α mRNA expression found in the AD model. Increased cortical β-amyloid (Aβ) levels were significantly reduced in the mouse model by both cannabinoids. Noteworthy both cannabinoids enhanced Aβ transport across choroid plexus cells in vitro.

Conclusions: In summary we have shown that chronically administered cannabinoid showed marked beneficial effects concomitant with inflammation reduction and increased Aβ clearance.

Keywords: Alzheimer’s disease, β-amyloid peptide, cannabinoids, glial activation, interleukin 6, anti-inflammatories, tumor necrosis factor-α

Background

Alzheimer’s disease (AD) is the major cause of dementia. The cognitive impairment is associated with the degeneration of particular subsets of neurons in regions involved in learning and memory processes. In addition another invariant feature of AD is neuroinflammation, considered a consequence of glial activation and reflected as astrogliosis and microglial activation, in particular around senile plaques, one of the pathological hallmarks of the disease, along neurofibrillary tangles. Indeed, lots of inflammatory parameters are found in AD brains [1,2]. Once initiated the inflammatory process it may contribute independently to neural dysfunction and cell death, establishing a self-perpetuating vicious cycle by which inflammation induces further neurodegeneration. The recognition of inflammation as
an important component in the disease led to the discovery that prolonged treatment with non-steroidal anti-inflammatory drugs (NSAIDs) had beneficial effects for AD. Indeed, several prospective works have shown that this kind of treatment markedly reduced the risk of suffering the neurologic condition, delayed its onset, ameliorated the symptomatic severity and slowed cognitive decline [3-5]. However their administration to already demented patients may be ineffective, suggesting the importance of early administration or, alternatively, the existence of additional targets of NSAIDs, besides cyclooxygenase inhibition. Nevertheless, other compounds with anti-inflammatory activity may be disease modifying drugs, which may delay onset or slow its progression, in contrast with the present AD palliative treatment.

Cannabinoids, whether plant derived, synthetic or endocannabinoids, interact with two well characterized cannabinoid receptors, CB1 and CB2 [6,7]. In addition, some cannabinoids may interact with other receptors, such as the TRPV1 receptor or the orphan receptor GPR55 [8,9]. The CB1 receptor is widely distributed, with a particularly high expression in brain, which contrasts with the limited expression of the CB2 receptor, which is characteristic of immune organs and cells [10]. In fact, while CB1 receptors are expressed by all types of cells in the brain (neurons and glial cells), CB2 are mainly localized in microglial cells [6,9-11], the resident immune cell of the brain.

We and others have proposed cannabinoids as preventive treatment for AD [12-14], based on their neuroprotective [15,16] and anti-inflammatory effects [11,17,18]. Indeed, cannabinoids are able to decrease the release of cytokines and nitric oxide in cultured microglial cells induced by lipopolysacharide [19,20] and Aβ addition [12,21]. In several in vitro studies cannabidiol (CBD), the major non-psychotropic constituent of cannabis, has shown to be neuroprotective against β-amyloid (Aβ) addition to cultured cells. This action was a consequence of reduction of oxidative stress and blockade of apoptosis [22], tau-phosphorylation inhibition through the Wnt/β-catenin pathway [23] and decreased iNOS expression and nitrite generation [24]. In vivo experiments have shown that several cannabinoids were effective at preventing Alzheimer’s disease related changes. In a previous work we have reported that synthetic cannabinoids, such as WIN55,212-2 and JWH-133, prevented the cognitive impairment, glial activation and neuronal marker loss in β-amyloid injected rats [12]. Enhancement of endocannabinoid levels by subchronic uptake inhibition reversed the increase in inflammatory parameters, such as COX-2, TNF-α and IL-1, in Aβ-injected mice, although cognitive impairment was only prevented in early treated mice [25]. Further, we have recently reported that CBD and WIN55,212-2 (WIN) inhibited both glial activation and cognitive deficits, as judged in the water maze test, and by a mechanism involving decreasing microglial activation, as shown in cultured microglial cells [20].

So far the possible effects of cannabinoids have not been studied in a genetic AD model, which mimics the amyloidosis and neuroinflammation [26,27] that occurs in the neurologic condition, in the absence of overt neurodegeneration [28]. Therefore in this work we have addressed the question whether cannabinoid agonists would ameliorate the cognitive deficits, neuroinflammation and altered Aβ levels in this AD model. To that end we have used WIN 55,212-2 (WIN), a mixed CB1/CB2 agonist [6] and JWH-133 (JWH) as selective CB2 agonist [29]. The CB2 selective agonist is devoid of psychoactivity, an advantage for its clinical endorsement, however we reasoned that a low dose of WIN may be free of psychoactive effects as well. The drugs were administered in drinking water [30] for a prolonged period, 4 months, to mimic a possible clinical setting. Given that cannabinoid treatment may be preventive, but not curative, administration of drugs was started at 7 months of age, when no cognitive dysfunction or plaque deposition exists, and it was prolonged for 4 months (eg until 11 months of age). We report here that such a treatment ameliorates cognitive performance, decreases neuroinflammation and Aβ levels, likely by increasing its transport to the periphery.

Results
Effect of cannabinoid oral treatment on cognitive impairment and glucose uptake by PET

In a previous work we assessed the effects of cannabinoids following intraventricular administration concomitant to Aβ injection for 7 days to rats [12]. This type of administration is not feasible in the Clinic, and is restricted to very few disease conditions. Other authors have used oral administration of 0.1 mg/kg/day tetrahydrocannabinol (THC) effectively [30]. Therefore, in this work we have chosen to administer cannabinoids in the drinking water to investigate their effects in the genetic model of AD. Given that we aimed a preventive treatment, it was initiated at 7 months of age when they do not exhibit Aβ deposition in plaques [28].

First we examined whether continuous oral treatment with a low dose (0.2 mg/kg/day for 4 months) of cannabinoids was able to rescue the cognitive impairment of Tg APP eleven months old mice in the novel object recognition test. Exploration activity was monitored during the training trial and all the animals displayed similar attention to the two identical objects. Wild type mice treated with vehicle were able to discriminate between the familiar object (Figure 1) and a novel object, exploring the latter for a longer time. WIN and JWH did not affect this behavior in wild type mice, even after prolonged treatment. As expected Tg APP mice did not distinguish both objects, showing cognitive impairment. In contrast Tg
A P P m i c e t r e a t w i t h t h e C B 2 s e l e c t i v e c a b i n a n o i d J W H s p e n t m o r e t i m e e x p l o r i n g t h e n o v e l o b j e c t , a l t h o u g h W I N w a s i n e f f e c t i v e a t t h a t r e s p e c t . 1 8 F D G u p t a k e i s s i g n i f i c a n t l y d e c r e a s e d i n a r e a s i n v o l v e d i n l e a r n i n g a n d m e m o r y b o t h i n A D p a t i e n t s a n d i n s u b j e c t s s h o w i n g m i l d c o g n i t i v e i m p a i r m e n t [ 3 1 ] . M o r e o v e r i t i s c o n s i d e r e d t o b e a n e a r l y m a r k e r o f t h e n e u r o l o g i c d i s e a s e . P r o l o n g e d W I N t r e a t m e n t r e d u c e d t h e u p t a k e i n w i l d t y p e m i c e s ( F i g u r e 2 B , C , D ) , w h i l e J W H w a s w i t h o u t e f f e c t . A s e x p e c t e d 1 2 m o n t h T g A P P v e h i c l e t r e a t e d m i c e h a d r e d u c e d 1 8 F D G u p t a k e ( 2 5 - 3 0 % ) d e p e n d i n g o n t h e r e g i o n o f i n t e r e s t ; F i g u r e 2 A , B , C , D ) . J W H c o n t i n u o u s a d m i n i s t r a t i o n f u l l y r e v e r s e d t h e r e d u c t i o n i n g l u c o s e u p t a k e i n T g A P P m i c e s ( F i g u r e 2 A , B , C , D ) , w h i c h w a s s l i g h t l y h i g h e r t h a n t h a t o f w i l d t y p e m i c e s ( a p p r o x i m a t e l y 1 5 % ) , w h i l e W I N w a s i n e f f e c t i v e o n t h a t r e s p e c t . T h e r e f o r e J W H , t h e C B 2 s e l e c t i v e a g o n i s t , w a s c a p a b l e o f i m p r o v i n g c o g n i t i v e i m p a i r m e n t a n d o f r e v e r s i n g t h e r e d u c t i o n i n 1 8 F D G u p t a k e i n c o r t i c a l a r e a s a n d h i p p o c a m p u s o f T g A P P .

Cannabinoids reduce microglial activation and inflammatory parameters in Tg APP mice cerebral cortex

Neuroinflammation is reflected in AD and its transgenic models brain as astrogliosis and microglial activation, particularly surrounding senile plaques [26,28]. GFAP immunohistochemistry showed similar staining patterns in hippocampus in the different groups studied (Figure 3 A and 3B), irrespective of the genotype or the treatment received. Similarly GFAP protein levels, as assessed by Western blotting, were maintained across the different groups (Figure 3 C and 3D). Microglial cell staining and density was assessed by using ionized Ca²⁺-binding adaptor molecule-1 (Iba-1) antibody. The antibody labeled resting microglial cells in wild type mice, characterized by the fine tortuous branching, which was unaffected by either of the cannabinoids used in the oral chronic treatment (Figure 4, A). Tg APP vehicle treated mice showed an increase (53%) in Iba-1 positive microglial cells compared with wild type mice (Figure 4, A and 4B). While continuous WIN treatment did not alter this increased density, the CB2 selective agonist JWH decreased cell density so that cell number accounted 83% of that of wild type mice (Figure 4 B). These results indicate that at this age Tg APP mice do not show astrogliosis, but they had microglial activation, which was effectively counteracted by JWH oral treatment.

Recent works have shown increased CB2 microglial expression following a lesion or in a neurodegeneration context [32], including AD brain [13,33]. We also addressed this issue by means of double immuno-fluorescence. We revealed CB2 expression in Iba-1 microglial cells (additional file 1 A1-3) in quinolinic acid injected striatum (additional file 2) and not in the contralateral striatum (additional file 1, B1-3), as expected. However there was no evident CB2 staining in any region examined of Tg APP mice (additional file 1, C1-3). Regarding CB2 protein expression Tg APP mice had similar levels compared to wild type mice which also received vehicle (Figure 5 A and 5B). JWH administration, but not WIN, decreased (45%) CB2 protein levels (Figure 5, B). Both WIN and JWH significantly decreased CB2 protein (Figure 5, B) in the AD model, which attained very low levels (around a 75%-80% reduction). We used Western analysis or qRT-PCR to assess possible changes in inflammatory parameters in cerebral cortex (Figure 5). JWH, but not WIN, decreased COX-2 expression in wild type mice (Figure 5 C and 5D). This parameter was markedly increased a 49% in Tg APP mice (Figure 5 D). Noteworthy, both cannabinoids effectively reversed COX-2 protein enhancement, reaching even lower levels than in wild type mice (40% and 60% respectively vs. wild type vehicle treated mice).

Different cytokines have been shown to be increased in AD brain and in its genetic model. IL-6 mRNA expression was similar across the different groups (Figure 5, E). As expected cortical TNF-α mRNA expression was dramatically increased (around 6 fold vs wild type vehicle treated mice; Figure 5 F). The cannabinoid agonists used
Figure 2 JWH oral administration rescued the decreased $^{18}$F-DG uptake in TgAPP assessed by PET. A: representative images (MR, $^{18}$F-DG uptake and merged) in hippocampus of wild type (Wt) and Tg APP vehicle treated mice. Continuous oral treatment of wild type mice with WIN decreased uptake in all regions studied (B: hippocampus; C: Frontal cortex; D: Temporo-parietal cortex). Tg APP showed decreased uptake which was normalized by JWH oral treatment (A-D). Animals were treated with vehicle or cannabinoids (0.2 mg/kg) in the drinking water for 4 months, starting at 7 months of age. Results are mean ± SEM (n = 4 mice/group) of the ratio of average radiactivity in a given region of interest (ROI) by the radiactivity in cerebellum (Cb) expressed as percentage. *p < 0.05, ** p < 0.01 vs vehicle treated mice; #p < 0.05 vs wild type-vehicle mice (ANOVA followed by Student’s t test).
in this study prevented this increase, although this cytokine expression continued to be higher than that of wild type mice (Figure 5, F).

Taken together these results demonstrate that continuous cannabinoid administration has anti-inflammatory activity given that different mediators were effectively counteracted in Tg APP.

Cannabinoids oral administration decreases β-amyloid levels and increases its transport through choroid plexus monolayers
The Tg APP model parallels the amyloidosis of the neurologic condition. Eleven month old Tg APP mice have no detectable insoluble (formic acid extracted) Aβ levels by ELISA. As expected no soluble human transgenic Aβ levels were detected in wild type mice, while Tg APP mice had high levels of Aβ1-40 (Figure 6, A) and detectable levels of the more amyloidogenic Aβ1-42 fragment (Figure 6, B). JWH decreased by 27% the levels of Aβ1-40, and a 30% similar reduction in Aβ1-42 was found following the administration of either WIN or JWH (Figure 6, A and 6B).

To determine the mechanism by which both cannabinoids reduce Aβ levels first we examined the effect of both compounds on Aβ release from cultured APP/PS1 glioma cells. There was no difference in the presence or the absence of drugs (data not shown) suggesting that neither the release nor the synthesis of Aβ was altered. Next we...
wondered whether the cannabinoids would reduce Aβ levels by enhancing its clearance, a therapeutic strategy intensively studied for AD treatment. Therefore we assessed Aβ transport across choroid plexus monolayers in vitro. Since there are contradictory reports on the presence of CB1 receptors in choroid plexus [34,35] first we performed stainings with CB1 and CB2 antibodies. We revealed the presence of both receptors in rat choroid plexus (Figure 6, C). Then we examined the possible time course of the transport of Aβ1-40 (5 μg/ml) added to the upper compartment, by measuring the amount of peptide in the lower compartment by Western blotting at different time points (Figure 6 D). In the absence of any drug the peptide was recovered at 12 h, and at longer times (24 and 48 h), after its addition to the upper compartment. However, the transport was much quicker in the presence of WIN or JWH (200 nM) and Aβ was mainly transported at shorter times (1-3 h; Figure 6 D). To quantify this transport we took advantage of ELISA assays and assessed peptide levels at 1 and 3 h after the addition of Aβ to the cell cultures (Figure 6 E). WIN and JWH promoted the same peptide transport both at 1 and 3 h, while almost no detectable Aβ crossed the choroid plexus cell monolayer in their absence (Figure 6 E). In summary, prolonged oral administration of cannabinoids effectively reduced Aβ levels in Tg APP brain, likely due to increased peptide clearance through the blood- or the CSF-barrier.

**Effect of prolonged oral treatment with cannabinoids on GSK3-β levels**

AD is characterized by the existence of increased tau phosphorylation, mainly by the action of GSK3-β, which is deregulated. We assessed by Western blotting total and pSer9-GSK3-β (inactive form) levels in cerebral cortex, from Wt and Tg APP mice following the different treatments. Cannabinoid agonist treatment did not change pSer9 GSK3-β protein levels in wild type mice. In contrast, there was a reduction (around 40%) in p-GSK3-β in the AD model which was normalized by WIN administration, but not JWH (28% decrease vs wild type vehicle treated mice). Total GSK3-β protein levels remained largely unchanged. Similarly no changes in the levels of either pSer21 GSK3-α or total GSK3-α protein levels were observed (Figure 7). Therefore, the pathological pSer9-GSK3-β activity was normalized by the CB1/CB2 mixed agonist WIN.

**Discussion**

In this work we describe several beneficial effects of the prolonged oral treatment with two cannabinoid agonists with different pharmacological profiles. Both cannabinoids were effective at decreasing the inflammatory parameters and Aβ levels. However, it was the CB2 selective agonist JWH that was able to prevent cognitive deficits and glucose metabolism reduction.

Our results differ from a recent work [36] reporting variable effects on water maze performance and fear conditioning, no changes in Aβ levels or plaque burden following subchronic treatment with the CB1/CB2 mixed agonist HU-210. Methodological differences may account for the results, since they used male and female double APP23/PS1 transgenic mice, at 4 (young) or 6-9 weeks of age, and a very low dose of the cannabinoid agonist (10 or 50 μg/kg) injected twice daily [14].

CB1 activation induces psychoactive effects. In fact mixed CB1/CB2 and CB1 selective agonists after acute
administration decrease motor activity and impair learning and memory [37–39], although at higher doses than the one we used in this study (0.2 mg/kg/day). However, chronic administration of those drugs induces tolerance to their acute effects in different behavioural tests [40,41]. Therefore, the fact that WIN did not affect learning in the novel object recognition test in wild type mice might suggest tolerance after prolonged administration. Similarly WIN was without effect on recognition memory of Tg APP mice. In contrast, CB₂ selective agonists, such as JWH, are devoid of psychoactivity after acute administration and does not alter motor activity [42, Martín-Moreno et al., in preparation] after systemic administration or object recognition memory following its intrahippocampal injection [43]. After prolonged administration to wild type mice JWH neither altered learning nor memory in the present work. Interestingly this compound effectively counteracted the cognitive impairment of Tg APP mice.

The brain is the organ with the highest glucose consumption, which is believed to be coupled to neural activity. The reduction in brain glucose uptake has been repeatedly demonstrated in AD patients [31,44], in particular in regions involved in memory, and it is highly
correlated with cognitive deficits. Prolonged oral WIN administration reduced glucose uptake, as measured by PET $^{18}$F-DG, in wild type mice in cortical regions and hippocampus. This result may be deleterious, in spite of the observation of no memory impairment in the cognitive test selected. In fact, previous autoradiographic work has reported either normal $^3$H-DG uptake in hippocampus or a decrease, depending on the dose of WIN [45] acutely administered. Decreased $^{18}$F-DG uptake in Tg APP in the present work is in essential agreement with previous reports, either by autoradiographic techniques [46] or PET [47]. Notably JWH administration for 4 months did not alter glucose uptake in wild type mice, while it completely abrogated the reduction observed in Tg APP. Brain activity in general, and cognition in particular rely on glucose metabolism [47], therefore the effects of the CB$_2$ agonist on both glucose utilization and recognition memory are of therapeutic interest.

Inflammation has several drawbacks including learning and memory impairment [48], in particular during ageing.

Figure 6 Cannabinoids decreased Aβ levels of Tg APP mice and increased transport through choroid plexus cell monolayer. A: Both cannabinoids significantly decreased Aβ$_{1-42}$ cortical levels. B: JWH decreased Aβ$_{1-40}$ cortical levels in Tg APP mice. Animals were treated with vehicle or cannabinoids (0.2 mg/kg) in the drinking water for 4 months, starting at 7 months of age. Results are mean ± SEM (n = 6-7 mice/group). C: rat choroid plexus express both CB$_1$ and CB$_2$ receptors. D: time-course of Aβ$_{1-40}$ transport through choroid plexus cells. Both cannabinoids (200 nM) reduced the transport time compared to untreated cultures (representative Western blot). E: Cannabinoids enhanced Aβ$_{1-40}$ transport through choroid plexus cells at 1 and 3 h after addition vs untreated control cultures (mean ± SEM, n = 4). E: *p < 0.05, ***p < 0.001 vs vehicle treated mice or cultures (Student’s t test).
Figure 7 WIN oral treatment counteracted decreased phospho-Ser9 GSK3β in cerebral cortex of Tg APP mice. A: representative Western blot of p-Ser9 GSK3β. B: optical density (OD). C: total-GSK3β. D: optical density (OD). E: representative Western blot of p-Ser21 GSK3α. F: optical density (OD). G: total-GSK3α in cerebral cortex. H: optical density (OD). Wild type (Wt) and Tg APP mice were treated with vehicle or cannabinoids (0.2 mg/kg) in the drinking water for 4 months, starting at 7 months of age. Results are mean ± SEM (n = 6-7 mice/group) *p < 0.05 vs wt-veh mice, # p < 0.05 vs Tg APP-vehicle treated mice; #p < 0.05 vs wild type vehicle treated mice (ANOVA followed by Student’s t test).
noted that although CB2 receptors could be expressed by
neurons [56] they are mainly expressed by microglia [12,19-21,25]. Indeed we found
no plaques with glial associated cells, although there was a
significant enhancement in microglial cell density in Tg APP mice. Continuous JWH treatment for 4 months normal-
ized this parameter, but WIN was ineffective. In dif-
f erent contexts (eg lesions) both astrocytes and microglia
could be engaged in inflammation. However in light of
those results we can ascribe the increase in inflammatory
mediators to microglial activation, given that there was
no overt astroglisis. COX-2 protein levels and TNF-α
mRNA expression is increased in AD and its transgenic
model [54,55]. Both cannabinoids signifcantly decreased
COX-2 and TNF-α, as expected, since both compounds
share CB2 receptor activation, as shown by the down-regu-
lation of its expression in Tg APP mice. It should be
noted that although CB2 receptors could be expressed by
some neurons [56] they are mainly expressed by micro-
glial cells [6,9-11], and are involved in the modulation of
several inflammatory mediators [12,19-21,25]. We did
expect an increase in CB2 receptor expression in the trans-
genic model given that Aβ addition to microglial cultures enhance it [21]. However, in Tg APP mice we
did not observe CB2 co-localization with Iba-1, which
contrasts with the microglial co-expression in AD brain
[13,33]. We neither found an increase by Western blot-
ing, in agreement with our previous results in AD patients or Aβ-injected rats [12]. This supports the
notion that at this age there is an ongoing glial activation of low magnitude in Tg APP and that cannabinoids
down-modulate this response.
Aβ removal is considered a therapeutic strategy in AD, promoted either by vaccination [57,58] or by
enhancing its clearance towards the periphery [59,60]. One of the most interesting findings of the present
work is the Aβ lowering ability of both cannabinoids, which we report for the first time. Prolonged oral JWH
treatment decreased Aβ1-40 levels in brain and both can-
nabinoids decreased the more amyloidogenic fragment,
Aβ1-42. Given that the drugs did not alter Aβ release we speculated that APP cleavage was not altered, and
therefore studied whether cannabinoids changed the peptide transport in vitro. Rat choroid plexus expressed
CB1, in agreement with [34], and also CB2 receptor pro-
tein, making feasible their activation by the drugs under
study. Cannabinoids favored Aβ transport, that was
mainly observed at shorter times (1-3 h) compared to
control experiments. This interesting effect merits
further study.
At variance with those efffects oral treatment with WIN, but not JWH, normalized the levels of GSK3-β in Tg
APP mice. Neurofibrillary tangles (NFTs), resulting from
an abnormal phosphorylation of microtubule-associated
tau proteins, represent a key pathological hallmark of
Alzheimer’s brain. GSK3-β is the kinase mainly responsi-
ble for tau hyperphosphorylation, therefore inhibiting its
activity is considered of therapeutic interest. The effect
of WIN after prolonged oral administration is in accordance
with reports showing a CB1 dependent increase in GSK3-
β phosphorylation in cultured cells [61], in brain after
acute cannabinoid agonist administration [62], and with
a reduction in tau phosphorylation [23]. Neurofibrillary
tangles are intraneuronal elements and neurons are in
general devoid of CB2 receptors. Therefore the effects of
WIN on GSK3-β, which were not mimicked by the CB2
selective agonist JWH, might be explained by its interac-
tion with CB1 receptors in neurons.
Given that our previous work had shown that cannabi-
noids were preventive against the Aβ efffects, both in
vitro and in vivo [12,20] we decided to start the continu-
ous oral treatment at 7 months of age. At this time Tg
APP mice do not have plaques and show normal learning
and memory compared to wild type mice. Nevertheless,
the treatment ended at 11 months of age when Tg APP
begin to show memory disruption. According to our
results the prolonged drug treatment decreased micro-
glial activation of Tg APP mice along several inflamma-
tory mediators, which were increased. However, ageing
alters microglial responsiveness (eg to Aβ production
and deposition), which is highly dynamic and context
dependent [63]. Therefore a potential caveat of our
results is that they may not be applicable to aged patho-
logical microglia as occurs in severe AD. However, a pre-
ventive treatment at very early stages of the disease may
be feasible and beneficial as has been shown with the
anti-inflammatory trifusal, both in amnestic mild cogni-
tively impaired patients [64] and in Tg APP mice [65].
Over the last decade important findings on the involve-
ment of the endocannabinoid system in AD has been
gathered. Indeed, in AD brain there is increased expres-
sion of CB2 receptors in microgilla and of fatty acid amide
hydrolase, the enzyme responsible for anandamide degra-
dation, in astrocytes around plaques [13]. However CB1
localization is markedly altered and its protein expres-
sion and functionality diminished [12]. Furthermore, molecular
rearrangements in different endocannabinoid system elements suggest that 2-AG signaling is increased, possibly contributing to synaptic failure in AD [66], while anandamide levels are decreased and are inversely correlated with Aβ levels [67]. Interestingly, the CB2 receptor expression has been reported to be increased both in the brain of AD patients [68] and in peripheral blood, where a significant correlation was found with the dementia score [69]. Finally, a CB2 PET radiotracer is accumulated in brains showing neuroinflammation (eg LPS injected and Tg APP/PS1 mice; [70]). These latter results suggest the importance of CB2 receptor as a biomarker of the neurologic disease, but also as a therapeutic target. CB2 receptor increased expression in AD appears to be a consequence of microglia activation, but more importantly they render microglia susceptible to cannabinoid modulation, decreasing the generation cytotoxic molecules and inhibiting microglial activation, while promoting its migratory activity [10,11,20].

Conclusions
In summary, cannabinoid agonists, in particular CB2 selective agonists, interfere with several interconnected events of importance in the pathophysiology of AD. These compounds by directly interacting with cannabinoid receptors, in particular CB2, decrease microglial activation thereby reducing inflammation and its consequences (eg cognitive deficits). At the same time they may indirectly have beneficial effects on microglial activation (eg decrease cytokine release) by lowering brain Aβ levels.

Methods
Animals and treatments
Tg APP transgenic mice were obtained via heterozygous breeding of mice expressing the 695 aa long isoform of the human APP containing a double mutation Lys 670-Asn, Met 671-Leu [52] (swedish mutation) under transcriptional control of the hamster prion promoter on a C57/BL6 breeding background. Male Tg APP and wild type littermates, used as controls, were 7 months age at the beginning of the experiments. Mice were group-housed (4-5 animals per cage) with a 12:12 h light/dark cycle and with ad libitum access to food and water. All of the experiments were performed according to ethical regulations on the use and welfare of experimental animals of the European Union and the Spanish Ministry of Agriculture, and the procedures were approved by the bioethical committee of the CSIC.

WIN 55,212-2 (WIN) and JWH-133 (JWH) were administered in the drinking water at a dose of 0.2 mg/kg/day using ethanol (0.1%) as vehicle. The amount of water drank by the animals was assessed every other day and the treatment was adjusted to their weight. There was no difference in the body weight or the ingested water between groups, all along the experiment, discarding a possible reinforcing effect of cannabinoids.

Animals were sacrificed by cervical dislocation followed by decapitation at 11 months of age. The brain was sagittally divided. One hemispheric was rapidly dissected on a cold plate, frozen on dry ice and stored at -80°C until assayed. The other hemisphere was immersion fixed in PF 4% in PB 0.1 M for 24 h, cryoprotected in sucrose 15% (24 h) and 30% (24 h) in PB, snap frozen in hexane (-60°C) and stored at -20°C until cut with a sliding microtome.

Novel object recognition test
The arena measured 40 × 40 cm, surrounded by 30-cm-high perimeter black walls, that was located in an isolated room that was novel to the animals. The floor of the arena was covered with used sawdust. The arena was monitored by a video-camera located above the arena. The procedure consisted in three visits to the arena in subsequent days. The first day mice were placed into the empty arena for 15 min (habituation). The second day they were allowed to explore two identical objects during two 10 min trials 5 min apart (training). On the third day (test), one of the objects was changed by a novel one, with different shape and color, and the mice explored the arena for 10 min. Data collection was carried out by the Ethovision software (Noldus, The Netherlands) and exploring was defined as “directing the nose at a distance equal to or less than 3 cm from the object or touching it with the nose”. The time spent exploring the familiar object and the new object was expressed as a percentage. Objects were cleaned before every exposure with acetic acid 0.1% to prevent any olfactory clues. Experiments were performed at the same time of the day (9.00-14.00 h).

18Fdeoxyglucose (18FDG) Positron Emission Tomography (PET)
Fasted mice were anesthetized with isoflurane (2%) and injected (ip) with 18FDG (11,1 MBq or 300 μCi/200 μl saline, PET Technologic Institute, Madrid). Thirty min later 18FDG uptake images of each mouse were acquired for 30 min by PET imaging (Albira PET, 8 detectors, Gem-Imaging, Spain; [71]). The regions of interest were previously delineated in magnetic resonance (MR) T2-weighted images (Bruker Biospin, Germany) of each animal. Quantification of the metabolic activity was performed by co-registering the PET images of the brains to their own MR image as described by [72]. In our case, the field of view (FOV) of the PET scanner is 80 × 80 × 40 mm and the number of pixels of the reconstructed tomographic image is 160 × 160 × 80 pixels, being the voxel size 0.5 mm³. Co-registration of the PET image to the MRI, leads to a reduction of the pixel size to 0.2 mm³, given the trilinear
interpolation done by the PMOD software (PMOD Technologies, version 2.9, Switzerland). The 18FDG uptake of the different brain areas were normalized to the 18FDG uptake in the cerebellum (considered as reference region).

Immunohistochemistry and image analysis
Immunostaining was performed on floating sections (35 μm) as described previously [12]. In brief, following several washes with PBS, the endogenous peroxidase was blocked (3% hydrogen peroxide in methanol), washed again, and incubated for 90 min in PB containing 0.2% Triton × 100 and 10% normal goat serum. Sections were incubated with the different antibodies in PB containing 0.2% Triton × 100 and 1% normal goat serum overnight at 4°C. Dilutions of antibodies were as follows: anti-GFAP (1:1500, Sigma); anti-Iba-1 (1:1000, WAKO) (additional file 2). Development was conducted by the ABC method (Pierce, Rockford, IL), and immunoreactivity was visualized by 3,3-diaminobenzidine oxidation as chromogen, with or without nickel enhancement. Images were acquired with Zeiss Axiocam high resolution digital color camera, using the same settings and the segmentation parameters (MCID softwares, InterFocus Imaging, UK) were constant for a given marker and experiment. The mean value for each animal per region results from the analysis of 5-6 sections.

Aβ levels
Aβ measurements were performed by two ELISA kits, one for each fragment (Aβ1-40 and Aβ1-42), from Biosource following the manufacturer instructions. The samples were sonicated (5 sec) in 10 vol of protein lysis buffer containing protease inhibitors (see Western blotting for details). The lysate was centrifuged (18,000 × g, for 10 min at 4°C). The supernatant was considered soluble and the pellets were further extracted by sonicating with formic acid and centrifuged. Prior to the Elisa the unsoluble samples were diluted 3 times with Tris 1 M, pH 10, while the soluble samples were diluted 5 times in Elisa buffer. The results were expressed as pg/mg of protein measured by the Bradford method, using BSA as standard.

Aβ transport
A double-chamber choroid plexus epithelial cell culture system mimicking the blood-cerebrospinal fluid (CSF) interface was used for in vitro studies, as previously described [59]. After seeding, the cells were incubated for 24 h and thereafter Aβ1-40 (5 μg/ml) was added to the lower chamber in the absence or presence of the cannabinoid agonists (500 nM). At different time points the medium was collected from the upper chamber, and the Aβ1-40 content was determined by immunoblotting. In other experiments Aβ1-40 levels were assessed by selective Elisa kits (Biosource) as described above.

Western blotting
Western blot was performed as described previously [61]. In brief, tissues were sonicated in lysis buffer, samples were centrifuged at high speed for 10 min, and supernatants were collected. Total protein was assessed by the Bio-Rad (Hercules, CA) protein assay. An aliquot of each sample (40 μg of protein) was separated by SDS-PAGE (10%), and proteins were transferred from the gels onto nitrocellulose membranes. The blots were blocked with 1% defatted dry milk for 1 h at room temperature and incubated overnight at 4°C with the following antibodies: anti-GFAP (1:10.000, DAKO), anti-CB2 (1:10.000, Affinity Bioreagents); anti-COX2 (1:100, Abcam); anti-p-GSK3β (1:5000, BD); anti-GSK3β (1:1.500, Cell Signaling) (additional file 2). Finally, samples were subjected to enhanced chemiluminescence and densitometric analysis. Band densitometric analysis was performed by Quantity One quantitation software (version 5.0; Bio-Rad) from film exposures; the background was subtracted, and the optical density percentage was obtained considering 100% the control samples within the same film. Tubulin was used as loading control. Every membrane contained samples from each treatment group, for comparison purposes.

The specificity of the CB2 antibodies used (additional file 2) was assessed by preincubating with the human anti- genic peptide (2 μ/ml overnight at 4°C under agitation), as stated in additional file 2, before its use in Western blotting, which resulted in blockade of the immunoreactive signal (see additional file 3).

Analysis of mRNA levels by quantitative real-time PCR
Total RNA from cortex was extracted using TRIzol reagent according to the manufacturer’s instructions (Invitrogen). To avoid interference with potential genomic DNA amplification, we treated 1 μg of total RNA with 1 μl DNase I (Invitrogen) plus 1 μl of 10× Buffer (Invitrogen). The samples were incubated at RT for 15 min. EDTA (25 mM) was added to the mixture and the samples were incubated at 65°C for 15 min to heat inactivate the DNase I. For cDNA synthesis a total of 1 μg of RNA from the different samples were reverse-transcribed for 75 min at 42°C using 5 U of avian myeloblastosis virus reverse transcriptase (Promega) in the presence of 20 U of RNasin (Promega). The real-time PCR reaction was performed in 25 μl using the fluorescent dye SYBR Green Master mix (Applied Biosystems) and a mixture of 5 pmol of reverse and forward primers. The primers used were for TNF-α forward primer 5’ CATCCTCTCAAAATTCGAGTGA-CAA 3’ and reverse primer 5’ TGGGATAGACAAGG- TACAACCC 3’ and for IL-6 forward primer 5’ GAGGA TACCACTCCCCACAGACC 3’ and reverse primer 5’ AAGTGCAATCAGTTGTTTATACA 3’. Quantification was performed on an ABI PRISM 7900 sequence detection
system (Applied Biosystems). PCR cycles proceeded as follows: initial denaturation for 10 min at 95°C, then 40 cycles of denaturation (15 sec, 95°C), annealing (30 sec, 60°C), and extension (30 sec, 60°C). The melting-curve analysis showed the specificity of the amplifications. Threshold cycle, which inversely correlates with the target mRNA level, was measured as the cycle number at which the reporter fluorescent emission appears above the background threshold (data not shown). Data analysis is based on the ΔCT method with normalization of raw data to a house-keeping gene (β-actin). All of the PCRs were performed in triplicate.

Statistical analysis
Statistical significance analysis was assessed by using one-way or two-way analysis of variance (ANOVA) followed by unpaired Student’s t test (version 5.0, Prism software, GraphPad, USA). A value of p < 0.05 was considered significant.

Additional material

Additional file 1: Co-localization of CB2 and Iba-1 immunostaining in quinolinic acid injected striatum. Iba-1 positive microglia in striatum also express CB2 receptor protein ipsilateral to the toxin injection, but was absent in the contralateral (unlesioned) striatum. Tg APP microglial cells are devoid of CB2 immunostaining.

Additional file 2: Additional methods. (quinolinic acid striatal lesion and blockade of CB2 antibodies with CB2 blocking peptide) and additional file 1, which includes the antibodies, commercial source and dilution, used in immunohistochemistry and Western blotting.

Additional file 3: Blockade of CB2 antibodies 744 and 746 with CB2 antigenic peptide. The CB2 peptide completely blocked immunostaining.

Abbreviations
AP: β-amyloid peptide; AD: Alzheimer’s disease; COX-2: cyclooxygenase; GSK3-β: glycogen synthase kinase 3-β; IL6: interleukin 6; TNF-α: tumor necrosis factor-α

Acknowledgements
We thank Dr. K. Mackie for anti-CB1 antibody and M. E. Fernández de Molina and S. Plazuelo for excellent technical assistance. We acknowledge Dr. I. Lastres-Becker for thoughtful comments and constructive discussion on the manuscript. This work was supported by the Spanish Ministry of Science and Technology (SAF 2005-02845 to M.L.C). A.M.M-M. was recipient a fellowship for multiple sclerosis. The authors declare that they have no competing interests.

Received: 19 September 2011 Accepted: 16 January 2012
Published: 16 January 2012

References
1. Akiyama H, Barger S, Barnum S, Bratt D, Bauer J, Cole GM, Cooper NR, Eikelboom P, Emmerling M, Fiegle BL, Finch CE, Frautschy S, Giffen WS, Hampel H, Hull M, Landreth G, Lue L, Nakr A, Mackenzie IR, McGee PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Strohmeyer R, Tooyoma I, Van Muyswinkel FL, Veerhuis R, Walker D, Webster S, Wegrynak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer’s disease. Neurobiol Aging 2000, 21:383-421.
2. Wyss-Coray T, Mucke L: Inflammation in neurodegenerative disease - a double-edged sword. Neuron 2002, 35:419-432.
3. Bredt JC, Welch KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM: Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995, 16:523-530.
4. In ‘t Veld BA, Lauer L, Hoes AW, Ott A, Hofman A, Breteler MM, Stricker BH: NSAIDs and incident Alzheimer’s disease. The Rotterdam Study. Neurobiol Aging 1998, 19:607-611.
5. McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: A review of 17 epidemiologic studies. Neurology 1997, 47:425-432.
6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
7. Piomelli D: The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003, 4:873-884.
8. Begg M, Pacher P, Bátka S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, Kunos G: Evidence for novel cannabinoid receptors. Pharmacol Ther 2005, 106:133-149.
9. Stella N: Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58:1017-1030.
10. Stella N: Cannabinoid signaling in glial cells. Glia 2004, 48:267-277.
11. Walter L, Stella N: Cannabinoids and neuroinflammation. Br J Pharmacol 2004, 141:775-785.
12. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML: Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of micromglial activation. J Neurosci 2005, 25:1004-1013.
13. Benito C, Nuñez E, Pazos MR, Tolón RM, Romero J: The endocannabinoid system and Alzheimer’s disease. Mol Neurobiol 2007, 36:75-81.
14. Campbell VA, Gowran A: Alzheimer’s disease: taking the edge off with cannabinoids? Br J Pharmacol 2007, 152:655-662.
15. Mechoulam R, Spatz M, Shohami E: Endocannabinoids and Neuroprotection. Sc STE 2002, 65.
16. van der Stelt M, Veldhuis WB, Maccarone M, Bär PR, Nicolay K, Veldink GA, Di Marco V, Vliegenthart JG: Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 2002, 26:137-146.
17. Correa FG, Mestre L, Docagne F, Borelli J, Guaza C: The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. Vitam Horm 2009, 81:207-230.
18. Klein WK: Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005, 5:400-411.
19. Cabral GA, Marciano-Cabral F: Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol 2005, 78:1192-1197.
20. Martín-Moreno AM, Reigada D, Ramírez BG, Mechouram R, Innamorato N, Cuadrado A, de Celábalos ML: Cannabinoid and other cannabinoïds reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharm 2011, 79:964-973.
21. Ehrt H, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytte RD: Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005, 2:29.
22. Iuvone T, Esposito G, Santamaria R, Di Rosa M, Izzo AA: Neuroprotective effect of cannabinol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004, 89:134-141.
23. Esposito G, De Filippis D, Carruccio R, Izzo AA, Iuvone T: The marijuana cannabinoid component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue PC12 cells. J Mol Med 2006, 84:253-258.
24. Esposito G, De Filippis D, Mauin MC, De Stefano D, Carruccio R, Iuvone T: Cannabinol inhibits nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NFκB involvement. Neurosci Lett 2006, 399:91-95.
25. van der Stelt M, Mazolla C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V: Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoids levels. Cell Mol Life Sci 2006, 63:1410-1424.
26. Faustiny SA, Yang F, Izzard M, Hyman B, Sado TC, Hsiao K, Cole GM: Microglial response to amyloid plaques in APPswe transgenic mice. J Pathol 1998, 187:307-317.
27. Masliah E, Ikonomovic MD, Murphey M, Schenk D, Games D: Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F amyloid precursor protein and Alzheimer's disease. J Neurosci 1996, 16:5795-5811.
28. Itzkan MC, McMama N, Fedorchak K, Hsiao K, Hyman BT: APPswe transgenic mice develop age-related A beta deposits and neuropsychological abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997, 56:953-973.
29. Huffman JW, Liddle J, Yu S, Aung MM, Aboot ME, Wiley JL, Martin BR: Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. J Mol Med 2011, 89:79-87.
30. Martín-Moreno AM, Reigada D, Ramírez BG, Mechouram R, Innamorato N, Cuadrado A, de Celábalos ML: Cannabinoid and other cannabinoïds reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharm 2011, 79:964-973.
31. Ehrt H, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytte RD: Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005, 2:29.
32. Iuvone T, Esposito G, Santamaria R, Di Rosa M, Izzo AA: Neuroprotective effect of cannabinol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004, 89:134-141.
33. Esposito G, De Filippis D, Carruccio R, Izzo AA, Iuvone T: The marijuana cannabinoid component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue PC12 cells. J Mol Med 2006, 84:253-258.
34. Esposito G, De Filippis D, Mauin MC, De Stefano D, Carruccio R, Iuvone T: Cannabinol inhibits nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NFκB involvement. Neurosci Lett 2006, 399:91-95.
35. van der Stelt M, Mazolla C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V: Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoids levels. Cell Mol Life Sci 2006, 63:1410-1424.
36. Faustiny SA, Yang F, Izzard M, Hyman B, Sado TC, Hsiao K, Cole GM: Microglial response to amyloid plaques in APPswe transgenic mice. J Pathol 1998, 187:307-317.
37. Masliah E, Ikonomovic MD, Murphey M, Schenk D, Games D: Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 1996, 16:5795-5811.
38. Itzkan MC, McMama N, Fedorchak K, Hsiao K, Hyman BT: APPswe transgenic mice develop age-related A beta deposits and neuropsychological abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997, 56:953-973.
39. Huffman JW, Liddle J, Yu S, Aung MM, Aboot ME, Wiley JL, Martin BR: Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. J Mol Med 2011, 89:79-87.
40. Martín-Moreno AM, Reigada D, Ramírez BG, Mechouram R, Innamorato N, Cuadrado A, de Celábalos ML: Cannabinoid and other cannabinoïds reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharm 2011, 79:964-973.
41. Ehrt H, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytte RD: Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005, 2:29.
42. Iuvone T, Esposito G, Santamaria R, Di Rosa M, Izzo AA: Neuroprotective effect of cannabinol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004, 89:134-141.
43. Esposito G, De Filippis D, Carruccio R, Izzo AA, Iuvone T: The marijuana cannabinoid component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue PC12 cells. J Mol Med 2006, 84:253-258.
44. Esposito G, De Filippis D, Mauin MC, De Stefano D, Carruccio R, Iuvone T: Cannabinol inhibits nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NFκB involvement. Neurosci Lett 2006, 399:91-95.
45. van der Stelt M, Mazolla C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V: Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoids levels. Cell Mol Life Sci 2006, 63:1410-1424.
46. Faustiny SA, Yang F, Izzard M, Hyman B, Sado TC, Hsiao K, Cole GM: Microglial response to amyloid plaques in APPswe transgenic mice. J Pathol 1998, 187:307-317.
47. Masliah E, Ikonomovic MD, Murphey M, Schenk D, Games D: Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 1996, 16:5795-5811.
48. Itzkan MC, McMama N, Fedorchak K, Hsiao K, Hyman BT: APPswe transgenic mice develop age-related A beta deposits and neuropsychological abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997, 56:953-973.
Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.

58. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Khodolenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandersluis T, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-\(\beta\) attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.

59. Carro E, Trejo JL, Gomez-Isa T, LeRoth D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-\(\beta\) levels. Nat Med 2002, 8:1390-1397.

60. Matsuo K, Yato M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Leme C, Duff K. Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003, 23:29-33.

61. Molina-Holgado E, Vela JM, Aizpurua-Martin A, Almazán G, Molina-Holgado F, Borell J, Guaza C. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002, 22:9742-9753.

62. Vassa A, Puighermanal E, Maldonado R. Regulation of P38/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 2007, 102:1105-1114.

63. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 2009, 64:110-122.

64. Gómez-Isla T, Blesa R, Boada M, Clarimón J, Del Ser T, Domenech G, Gómez-Moreno AM, Keimpema E, Tanila H, Watanabe M, Mackie K, Martín-Moreno AM, Martín-Moreno AM, Keimpema E, Tanila H, Watanabe M, Mackie K, Hortobágyi T, de Ceballos ML, Harkany T. Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease. Brain 2011, 134:1041-1060.

65. Jung KM, Astin G, Yasar S, Vilešek V, Cribs DH, Head E, Cotman CW, Piomelli D. An amyloid \(B\beta(42)\)-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer’s disease. Neurobiol Aging 2011.

66. Grünblatt E, Zander N, Bartl J, Jie L, Monoranu CM, Arzberger T, Raab R, Rogge L, Gérlach M, Rederer P. Comparison analysis of gene expression patterns between sporadic Alzheimer’s and Parkinson’s disease. J Alzheimers Dis 2007, 10:291-311.

67. Grünblatt E, Bartl J, Zettehmayer S, Ringet TM, Bauer P, Rederer P, Jacob CP. Gene expression as peripheral biomarkers for sporadic Alzheimer’s disease. J Alzheimers Dis 2009, 16:627-634.

68. Hori A, Gao Y, Raveed HT, Finley P, Valentine H, Wong DF, Endres CJ, Savonienko AV, Dannals RF. Synthesis and biodistribution of [\(^{11}\)C]-\(^{83}\)N3, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg Med Chem 2010, 18:5202-5207.

69. Bocan B, O’Brien TJ. Application of coregistration for imaging of animal models of epilepsy. Epilepsia 2007, 48(Suppl 4):S2-89.